Hikma Pharmaceutical | HIK - Gross Profit On Sales


Hikma Pharmaceutical reported $362.5M in Gross Profit on Sales for its fiscal semester ending in June of 2025.





Gross Profit On Sales Change Date
Almirall EUR 429.87M 180.02M Dec/2025
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Autolus Therapeutics Ltd USD 1.65M 2.69M Mar/2026
Bayer EUR 8.17B 1.24B Mar/2026
Fresenius EUR 1.55B 16M Jun/2026
Genmab DKK 831M 146M Mar/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Orion EUR 339.9M 85.9M Jun/2026
Recordati EUR 497.97M 12.85M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025